Jim O'Neill

Jim O'Neill

economist United Kingdom

Jim O'Neill is a prominent British economist and former chief economist at Goldman Sachs, recognized for his influential views on global economic trends. He gained media attention recently for suggesting that the United Kingdom should leverage its position in the G7 to discuss reducing trade barriers in response to escalating tariffs imposed by the U.S. under President Trump, particularly with respect to major economies like China and India.

Born on Oct 29, 1961 (64 years old)

Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
67,802
Power
2,311$
Sentiment
5.27
Countries Mentioned
Country Mentions Sentiment Dominance + Persistence x Population = Reach x GDP (millions) = Power
Taiwan 2 5.00 0.25% +0% 23,816,775 60,143 $670,000 1,692$
Switzerland 1 6.00 0.09% +0% 8,654,622 7,659 $700,000 619$
Totals 3 32,471,397 67,802 $1,370,000 2,311$
Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Switzerland Switzerland: Jim O’Neill confirmed the allegations against the health company associated with Abukar Dahir Osman. 6

Neue Zürcher Zeitung: Trotz Armut und Skandalen: Somalia präsidiert den Uno-Sicherheitsrat

Guyana Guyana: Jim O’Neill is the acting head of the U.S. Centers for Disease Control and Prevention appointed by Kennedy. 4

Stabroek News: Kennedy's advisers scrap hepatitis B vaccine guidance for most children in major policy shift

United States United States: Jim O'Neill, the current acting director of the Centers for Disease Control and Prevention, has also been highlighting that among the federal funds that are improperly going to illegal immigrants. 6

Fox News: Trump vows to reclaim over $1B misused by states for illegal immigrant healthcare

United States United States: Jim O'Neill, the acting director of the US Centers for Disease Control and Prevention, called for vaccine makers to develop separate shots against measles, mumps, and rubella. 5

CNN: Acting CDC director, citing Trump directive, calls for MMR shot to be split into three despite no evidence of benefit